China To Fund API Makers To Promote Exports
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The Chinese government will spend RMB 5 billion ($760 million) to upgrade drug manufacturing quality assurance in an effort to help active pharmaceutical ingredient makers comply with global good manufacturing practices so they can export to the U.S. and Europe, an unnamed government official told the Shanghai Securities News
You may also be interested in...
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
China Should Focus On APIs And Pharmaceutical Preparations - CPEA Chairman
The China Pharmaceutical Enterprises Association's Chairman Yu Mingde remarked that China's pharmaceutical industry should focus on developing both APIs and pharmaceutical preparations
China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines
SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China